GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akouos Inc (NAS:AKUS) » Definitions » Gross Profit

Akouos (Akouos) Gross Profit : $0.00 Mil (TTM As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Akouos Gross Profit?

Akouos's gross profit for the three months ended in Sep. 2022 was $0.00 Mil. Akouos's gross profit for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Akouos's gross profit for the three months ended in Sep. 2022 was $0.00 Mil. Akouos's Revenue for the three months ended in Sep. 2022 was $0.00 Mil. Therefore, Akouos's Gross Margin % for the quarter that ended in Sep. 2022 was N/A%.

Akouos had a gross margin of N/A% for the quarter that ended in Sep. 2022 => No sustainable competitive advantage


Akouos Gross Profit Historical Data

The historical data trend for Akouos's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akouos Gross Profit Chart

Akouos Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Gross Profit
- - - -

Akouos Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Akouos's Gross Profit

For the Biotechnology subindustry, Akouos's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akouos's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akouos's Gross Profit distribution charts can be found below:

* The bar in red indicates where Akouos's Gross Profit falls into.



Akouos Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Akouos's Gross Profit for the fiscal year that ended in Dec. 2021 is calculated as

Gross Profit (A: Dec. 2021 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Akouos's Gross Profit for the quarter that ended in Sep. 2022 is calculated as

Gross Profit (Q: Sep. 2022 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Akouos's Gross Margin % for the quarter that ended in Sep. 2022 is calculated as

Gross Margin % (Q: Sep. 2022 )=Gross Profit (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Akouos  (NAS:AKUS) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Akouos had a gross margin of N/A% for the quarter that ended in Sep. 2022 => No sustainable competitive advantage


Akouos Gross Profit Related Terms

Thank you for viewing the detailed overview of Akouos's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Akouos (Akouos) Business Description

Traded in Other Exchanges
N/A
Address
645 Summer Street, Suite 200, Boston, MA, USA, 02210
Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders.
Executives
Kearny Acquisition Corp 10 percent owner LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Lilly Eli & Co 10 percent owner LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Jennifer Anne Wellman officer: Chief Operating Officer C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
Sachiyo Minegishi officer: Chief Financial Officer C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
5am Ventures V, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Maha Katabi 10 percent owner SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Pivotal Bioventure Partners Fund I G.p., L.p. 10 percent owner 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Heather Preston director, 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102

Akouos (Akouos) Headlines

From GuruFocus

FEDERATED HERMES, INC. Buys 2, Sells 3 in 2nd Quarter

By GuruFocus Research GuruFocus Editor 09-16-2022